Matrix metalloproteinases in skeletal muscles: Friends or foes?

Neurobiology of Disease

Volumn 48, Issue 3, 2012, Pages 508-518

  Alameddine, Hala S ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Cell migration; Cell therapy; MMPs; Muscle remodeling; Muscular dystrophy; Neuromuscular diseases; TIMPs

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 26; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ENZYME REGULATION; ENZYME STRUCTURE; EXPERIMENTAL MODEL; HUMAN; IN VITRO STUDY; MOLECULAR BIOLOGY; MUSCLE CELL; MUSCLE INJURY; MUSCLE REGENERATION; MUSCULAR DYSTROPHY; MYOPATHY; MYOSITIS; NEUROMUSCULAR DISEASE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKELETAL MUSCLE;

ANIMALS; HUMANS; MATRIX METALLOPROTEINASES; MUSCLE, SKELETAL; NEUROMUSCULAR DISEASES;

EID: 84865285291     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.07.023     Document Type: Review

References (182)

1. Akoolel S., et al. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol. Cell. Biol. 2003, 23:4901-4916.
2. Allen D.L., et al. Growth factor stimulation of matrix metalloproteinase expression and myoblast migration and invasion in vitro. Am. J. Physiol. Cell Physiol. 2003, 284:C805-C815.
3. Andolfo A., et al. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb. Haemost. 2002, 88:298-306.
4. Balcerzak D., et al. Coordinated expression of matrix-degrading proteinases and their activators and inhibitors in bovine skeletal muscle. J. Anim. Sci. 2001, 79:94-107.
5. Bani C., et al. Pattern of metalloproteinase activity and myofiber regeneration in skeletal muscles of mdx mice. Muscle Nerve 2008, 37:583-592.
6. Barnes B.R., et al. Alterations in mRNA and protein levels of metalloproteinases-2, -9, and -14 and tissue inhibitor of metalloproteinase-2 responses to traumatic skeletal muscle injury. Am. J. Physiol. Cell Physiol. 2009, 297:C1501-C1508.
7. Baum O., et al. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases. J. Vasc. Res. 2007, 44:202-213.
8. Bedair H., et al. Matrix metalloproteinase-1 therapy improves muscle healing. J. Appl. Physiol. 2007, 102:2338-2345.
9. Berthon P., et al. Regulation of ubiquitin-proteasome system, caspase enzyme activities, and extracellular proteinases in rat soleus muscle in response to unloading. Pflugers Arch. 2007, 454:625-633.
10. Beuche W., et al. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport 2000, 11:3419-3422.
11. Bourboulia D., Stetler-Stevenson W.G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin. Cancer Biol. 2010, 20:161-168.
12. Brew K., Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. BBA - Mol Cell Res. 2010, 1803:55-71.
13. Brew K., et al. Tissue inhibitors of metalloproteinases: evolution, structure and function. BBA-Protein Struct M. 2000, 1477:267-283.
14. Brown M.D., Hudlicka O. Modulation of physiological angiogenesis in skeletal muscle by mechanical forces: involvement of VEGF and metalloproteinases. Angiogenesis 2003, 6:1-14.
15. Butler G.S., et al. Membrane protease degradomics: proteomic identification and quantification of cell surface protease substrates. Methods Mol. Biol. 2009, 528:159-176.
16. Butler G.S., et al. Identification of cellular MMP substrates using quantitative proteomics: isotope-coded affinity tags (ICAT) and isobaric tags for relative and absolute quantification (iTRAQ). Methods Mol. Biol. 2010, 622:451-470.
17. Carmeli E., et al. Tetracycline therapy for muscle atrophy due to immobilization. J. Musculoskelet. Neuronal Interact. 2009, 9:81-88.
18. Caron N.J., et al. Increased myogenic potential and fusion of matrilysin-expressing myoblasts transplanted in mice. Cell Transplant. 1999, 8:465-476.
19. Cauwe B., et al. Multidimensional degradomics identifies systemic autoantigens and intracellular matrix proteins as novel gelatinase B/MMP-9 substrates. Integr Biol (Camb) 2009, 1:404-426.
20. Chaudhary A.K., et al. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J. Biomed. Sci. 2010, 17:10.
21. Chen X., Li Y. Role of matrix metalloproteinases in skeletal muscle: migration, differentiation, regeneration and fibrosis. Cell Adh. Migr. 2009, 3:337-341.
22. Chicoine E., et al. Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem. Biophys. Res. Commun. 2002, 297:765-772.
23. Chin J.R., Werb Z. Matrix metalloproteinases regulate morphogenesis, migration and remodeling of epithelium, tongue skeletal muscle and cartilage in the mandibular arch. Development 1997, 124:1519-1530.
24. Choi Y.C., Dalakas M.C. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 2000, 54:65-71.
25. Clark I.M., et al. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell B. 2008, 40:1362-1378.
26. Clutterbuck A.L., et al. Targeting matrix metalloproteinases in inflammatory conditions. Curr. Drug Targets 2009, 10:1245-1254.
27. Couch C.B., Strittmatter W.J. Rat myoblast fusion requires metalloendoprotease activity. Cell 1983, 32:257-265.
28. Couch C.B., Strittmatter W.J. Specific blockers of myoblast fusion inhibit a soluble and not the membrane-associated metalloendoprotease in myoblasts. J. Biol. Chem. 1984, 259:5396-5399.
29. Coussens L.M., et al. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
30. Dahiya S., et al. Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice. Hum. Mol. Genet. 2011, 20:4345-4359.
31. Davies J.E., et al. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat. Med. 2005, 11:672-677.
32. Dean R.A., Overall C.M. Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol. Cell. Proteomics 2007, 6:611-623.
33. Dehne N., et al. Activation of HIF-1 in skeletal muscle cells after exposure to damaged muscle cell debris. Shock 2011, 35:632-638.
34. Demestre M., et al. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J. Neuroimmunol. 2005, 159:146-154.
35. Dennis R.A., et al. Muscle expression of genes associated with inflammation, growth, and remodeling is strongly correlated in older adults with resistance training outcomes. Physiol. Genomics 2009, 38:169-175.
36. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25:9-34.
37. Duffy M.J., et al. The role of ADAMs in disease pathophysiology. Clin. Chim. Acta 2009, 403:31-36.
38. Echizenya M., et al. The membrane-anchored MMP-regulator RECK is a target of myogenic regulatory factors. Oncogene 2005, 24:5850-5857.
39. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
40. El Fahime E., et al. In vivo migration of transplanted myoblasts requires matrix metalloproteinase activity. Exp. Cell Res. 2000, 258:279-287.
41. English W.R., et al. Catalytic activities of membrane-type 6 matrix metalloproteinase (MMP25). FEBS Lett. 2001, 491:137-142.
42. Fadic R., et al. Increase in decorin and biglycan in Duchenne muscular dystrophy: role of fibroblasts as cell source of these proteoglycans in the disease. J. Cell. Mol. Med. 2006, 10:758-769.
43. Fahling M., et al. Role of nucleolin in posttranscriptional control of MMP-9 expression. Biochim. Biophys. Acta 2005, 1731:32-40.
44. Fang L., et al. MMP-2 and MMP-9 are elevated in spinal cord and skin in a mouse model of ALS. J. Neurol. Sci. 2010, 294:51-56.
45. Fanjul-Fernandez M., et al. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. BBA-Mol Cell Res. 2010, 1803:3-19.
46. Ferre P.J., et al. Longitudinal analysis of gene expression in porcine skeletal muscle after post-injection local injury. Pharmacol. Res. 2007, 24:1480-1489.
47. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Tar. 2003, 7:385-397.
48. Fiotti N., et al. Body composition and muscular strength changes after moderate activity: association with matrix metalloproteinase polymorphisms. Arch. Gerontol. Geriatr. 2009, 49(Suppl. 1):83-94.
49. Folgueras A.R., et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Dev. Biol. 2004, 48:411-424.
50. Frisdal E., et al. Increased expression of gelatinases and alteration of basement membrane in rat soleus muscle following femoral artery ligation. Neuropathol. Appl. Neurobiol. 2000, 26:11-21.
51. Fu X., et al. Oxidative cross-linking of tryptophan to glycine restrains matrix metalloproteinase activity: specific structural motifs control protein oxidation. J. Biol. Chem. 2004, 279:6209-6212.
52. Fukushima K., et al. Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ). BMC Musculoskelet. Disord. 2007, 8:54.
53. Gargioli C., et al. PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle. Nat. Med. 2008, 14:973-978.
54. Geesink G.H., Veiseth E. Muscle enzymes: proteinases. Hand Book of Muscle Foods Analysis 2009, CRC Press, Boca Raton. L.M.L. Nollet, F. Toldra (Eds.).
55. Giannelli G., et al. Matrix metalloproteinase imbalance in muscle disuse atrophy. Histol. Histopathol. 2005, 20:99-106.
56. Girgenrath M., et al. Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Ann. Neurol. 2009, 65:47-56.
57. Gomis-Ruth F.X. Structural aspects of the metzincin clan of metalloendopeptidases. Mol. Biotechnol. 2003, 24:157-202.
58. Gordon P.H., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007, 6:1045-1053.
59. Griffin M.O., et al. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol. Res. 2011, 63:102-107.
60. Gu Z., et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002, 297:1186-1190.
61. Guérin C.W., Holland P.C. Synthesis and secretion of matrix-degrading metalloproteases by human skeletal muscle satellite cells. Dev. Dyn. 1995, 202:91-99.
62. Haas T.L., et al. Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H1540-H1547.
63. Hadler-Olsen E., et al. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011, 278:28-45.
64. Heissig B., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002, 109:625-637.
65. Hnia K., et al. Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice. Am. J. Pathol. 2007, 170:633-643.
66. Hnia K., et al. L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am. J. Pathol. 2008, 172:1509-1519.
67. Holmbeck K., et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99:81-92.
68. Hurnaus S., et al. Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders. Eur. Neurol. 2006, 55:204-208.
69. Hwang I.K., et al. A proteomic approach to identify substrates of matrix metalloproteinase-14 in human plasma. Biochim. Biophys. Acta 2004, 1702:79-87.
70. Ito H., et al. Prior culture with concanavalin A increases intramuscular migration of transplanted myoblast. Muscle Nerve 1998, 21:291-297.
71. Jaworski D.M., et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2)-deficient mice display motor deficits. J. Neurobiol. 2006, 66:82-94.
72. Kaar J.L., et al. Matrix metalloproteinase-1 treatment of muscle fibrosis. Acta Biomater. 2008, 4:1411-1420.
73. Kafadar K.A., et al. Sca-1 expression is required for efficient remodeling of the extracellular matrix during skeletal muscle regeneration. Dev. Biol. 2009, 326:47-59.
74. Kandasamy A.D., Schulz R. Glycogen synthase kinase-3beta is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts. Cardiovasc. Res. 2009, 83:698-706.
75. Kandasamy A.D., et al. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc. Res. 2010, 85:413-423.
76. Kherif S., et al. Matrix metalloproteinases MMP-2 and MMP-9 in denervated muscle and injured nerve. Neuropathol. Appl. Neurobiol. 1998, 24:309-319.
77. Kherif S., et al. Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev. Biol. 1999, 205:158-170.
78. Kieseier B.C., et al. Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain 2001, 124:341-351.
79. Kleifeld O., et al. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products. Nat. Biotechnol. 2010, 28:281-288.
80. Klein T., Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011, 41:271-290.
81. Knoblauch A., et al. The binding of Mss4 to alpha-integrin subunits regulates matrix metalloproteinase activation and fibronectin remodeling. FASEB J. 2007, 21:497-510.
82. Koskinen S.O., et al. Serum concentrations of collagen degrading enzymes and their inhibitors after downhill running. Scand. J. Med. Sci. Sports 2001, 11:9-15.
83. Kriz J., et al. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2002, 10:268-278.
84. Kumar A., et al. Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. Am. J. Pathol. 2010, 177:248-260.
85. Kunugi S., et al. Inhibition of matrix metalloproteinases reduces ischemia-reperfusion acute kidney injury. Lab. Invest. 2011, 91:170-180.
86. Kwan J.A., et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J. 2004, 18:690-692.
87. Lambert E., et al. TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol. 2004, 49:187-198.
88. Lewis M.P., et al. Gelatinase-B (matrix metalloproteinase-9; MMP-9) secretion is involved in the migratory phase of human and murine muscle cell cultures. J. Muscle Res. Cell Motil. 2000, 21:223-233.
89. Li H., et al. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum. Mol. Genet. 2009, 18:2584-2598.
90. Liu X. Emerging ideas: matrix metalloproteinase-2 in muscle atrophy. Clin. Orthop. Relat R. 2011, 469:1797-1799.
91. Liu X., et al. Role of gelatinases in disuse-induced skeletal muscle atrophy. Muscle Nerve 2010, 41:174-178.
92. Lluri G., Jaworski D.M. Regulation of TIMP-2, MT1-MMP, and MMP-2 expression during C2C12 differentiation. Muscle Nerve 2005, 32:492-499.
93. Lluri G., et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) regulates neuromuscular junction development via a beta1 integrin-mediated mechanism. J. Neurobiol. 2006, 66:1365-1377.
94. Lo I.K., et al. Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase mRNA levels are specifically altered in torn rotator cuff tendons. Am. J. Sports Med. 2004, 32:1223-1229.
95. Lolmede K., et al. Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. J. Leukoc. Biol. 2009, 85:779-787.
96. Lopez-Otin C., Overall C.M. Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol. 2002, 3:509-519.
97. Lorenzl S., et al. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J. Neurol. Sci. 2003, 207:71-76.
98. Lorenzl S., et al. The matrix metalloproteinases inhibitor Ro 26-2853 extends survival in transgenic ALS mice. Exp. Neurol. 2006, 200:166-171.
99. Manicone A.M., McGuire J.K. Matrix metalloproteinases as modulators of inflammation. Semin. Cell Dev. Biol. 2008, 19:34-41.
100. Meng J., et al. Stem cells to treat muscular dystrophies - where are we?. Neuromuscul Disord. 2010, 21:4-12.
101. Mignatti P., Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 1993, 73:161-195.
102. Miyazaki D., et al. Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. Hum. Mol. Genet. 2011, 9:1787-1799.
103. Mohammad G., Kowluru R.A. Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction. Lab. Invest. 2010, 90:1365-1372.
104. Moore C.S., Crocker S.J. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am. J. Pathol. 2012, 180:12-16.
105. Morgan J., Alameddine H.S. Stem cell based therapy for muscular dystrophies: cell types and environmental factors influencing their efficacy. InTech 2012, Available from: http://www.intechopen.com/books/muscular-dystrophy/stem-cell-based-therapy-for-muscular-dystrophies-cell-types-and-environmental-factors-influencing-th. M. Hegde, A. Ankala (Eds.).
106. Morgan J.E., Partridge T.A. Cell transplantation and gene therapy in muscular dystrophy. Bioessays 1992, 14:641-645.
107. Morgan J., et al. MMP-9 overexpression improves myogenic cell migration and engraftment. Muscle Nerve 2010, 42:584-595.
108. Morrison C.J., et al. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr. Opin. Cell Biol. 2009, 21:645-653.
109. Murphy G. Fell-Muir Lecture: metalloproteinases: from demolition squad to master regulators. Int. J. Exp. Pathol. 2010, 91:303-313.
110. Nadarajah V.D., et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul. Disord. 2011, 21:569-578.
111. Nagamine Y., et al. Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb. Haemost. 2005, 93:661-675.
112. Nagase H., Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 1999, 274:21491-21494.
113. Nie J., Pei D. Rapid inactivation of alpha-1-proteinase inhibitor by neutrophil specific leukolysin/membrane-type matrix metalloproteinase 6. Exp. Cell Res. 2004, 296:145-150.
114. Niebroj-Dobosz I., et al. Matrix metalloproteinases in serum of Emery-Dreifuss muscular dystrophy patients. Acta Biochim. Pol. 2009, 56:717-722.
115. Niebroj-Dobosz I., et al. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2010, 17:226-231.
116. Nishimura T., et al. Inhibition of matrix metalloproteinases suppresses the migration of skeletal muscle cells. J. Muscle Res. Cell Motil. 2008, 29:37-44.
117. Oh J., et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107:789-800.
118. Oh J., et al. Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice. Oncogene 2004, 23:5041-5048.
119. Ohtake Y., et al. Multifunctional roles of MT1-MMP in myofiber formation and morphostatic maintenance of skeletal muscle. J. Cell Sci. 2006, 119:3822-3832.
120. Okamoto T., et al. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J. Biol. Chem. 2001, 276:29596-29602.
121. Overall C.M., Blobel C.P. In search of partners: linking extracellular proteases to substrates. Nat. Rev. Mol. Cell Biol. 2007, 8:245-257.
122. Overall C.M., et al. Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biol. Chem. 2002, 383:1059-1066.
123. Pallafacchina G., et al. An adult tissue-specific stem cell in its niche: a gene profiling analysis of in vivo quiescent and activated muscle satellite cells. Stem Cell Res. 2010, 4:77-91.
124. Parks W.C., et al. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 2004, 4:617-629.
125. Pasternak B., Aspenberg P. Metalloproteinases and their inhibitors - diagnostic and therapeutic opportunities in orthopedics. Acta Orthop. 2009, 80:693-703.
126. Pavlaki M., Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 2003, 22:177-203.
127. Peviani S.M., et al. MMP-2 is not altered by stretching in skeletal muscle. Int. J. Sports Med. 2009, 30:550-554.
128. Peviani S.M., et al. Stretching and electrical stimulation regulate the metalloproteinase-2 in rat denervated skeletal muscle. Neurol. Res. 2009, 32:891-896.
129. Piers A.T., et al. Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal mice. Neuromuscul. Disord. 2011, 21:132-141.
130. Radley H.G., et al. Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. Neuromuscul. Disord. 2008, 18:227-238.
131. Reznick A.Z., et al. Expression of matrix metalloproteinases, inhibitor, and acid phosphatase in muscles of immobilized hindlimbs of rats. Muscle Nerve 2003, 27:51-59.
132. Ries C., et al. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 2007, 109:4055-4063.
133. Rivera S., et al. Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?. J. Neurosci. 2010, 30:15337-15357.
134. Roach D.M., et al. Up-regulation of MMP-2 and MMP-9 leads to degradation of type IV collagen during skeletal muscle reperfusion injury; protection by the MMP inhibitor, doxycycline. Eur. J. Vasc. Endovasc. 2002, 23:260-269.
135. Rodriguez D., et al. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. BBA- Mol Cell Res. 2010, 1803:39-54.
136. Rosenberg G.A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009, 8:205-216.
137. Roy S., et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 2009, 82:21-29.
138. Rullman E., et al. A single bout of exercise activates matrix metalloproteinase in human skeletal muscle. J. Appl. Physiol. 2007, 102:2346-2351.
139. Rullman E., et al. Endurance exercise activates matrix metalloproteinases in human skeletal muscle. J. Appl. Physiol. 2009, 106:804-812.
140. Russo T.L., et al. Electrical stimulation increases matrix metalloproteinase-2 gene expression but does not change its activity in denervated rat muscle. Muscle Nerve 2008, 37:593-600.
141. Sampieri C.L., et al. Activation of p38 and JNK MAPK pathways abrogates requirement for new protein synthesis for phorbol ester mediated induction of select MMP and TIMP genes. Matrix Biol. 2008, 27:128-138.
142. Sariahmetoglu M., et al. Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J. 2007, 21:2486-2495.
143. Schoser B.G., Blottner D. Matrix metalloproteinases MMP-2, MMP-7 and MMP-9 in denervated human muscle. Neuroreport 1999, 10:2795-2797.
144. Schoser B.G.H., et al. Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers. Acta Neurol. Scand. 2002, 105:309-313.
145. Serrano A.L., Munoz-Canoves P. Regulation and dysregulation of fibrosis in skeletal muscle. Exp. Cell Res. 2010, 316:3050-3058.
146. Shiomi T., et al. Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol. Int. 2010, 60:477-496.
147. Shiryaev S.A., et al. Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One 2009, 4:e4952.
148. Soon C.P., et al. Serum matrix metalloproteinase-9 activity is dysregulated with disease progression in the mutant SOD1 transgenic mice. Neuromuscul. Disord. 2010, 20:260-266.
149. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 2007, 87:1285-1342.
150. Starr A.E., et al. Biochemical characterization and N-terminomics analysis of leukolysin, the membrane-type 6 matrix metalloprotease (MMP25): chemokine and vimentin cleavages enhance cell migration and macrophage phagocytic activities. J. Biol. Chem. 2012, 287:13382-13395.
151. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Biol. 2001, 17:463-516.
152. Stetler-Stevenson W. Tissue Inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci. Signal. 2008, 1:re6.
153. Stetler-Stevenson W.G. The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev. 2008, 27:57-66.
154. Stevenson E.J., et al. Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. J. Physiol. 2003, 551:33-48.
155. Stocker W., Bode W. Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr. Opin. Struct. Biol. 1995, 5:383-390.
156. Stocker W., et al. The metzincins - topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 1995, 4:823-840.
157. Sun G., et al. Elevated plasma levels of tissue inhibitors of metalloproteinase-1 and their overexpression in muscle in human and mouse muscular dystrophy. J. Neurol. Sci. 2010, 297:19-28.
158. Tang Y., et al. Inhibition of the IKK/NF-kappaB pathway by AAV gene transfer improves muscle regeneration in older mdx mice. Gene Ther. 2010, 17:1476-1483.
159. Thornton G.M., et al. Changes in mechanical loading lead to tendonspecific alterations in MMP and TIMP expression: influence of stress deprivation and intermittent cyclic hydrostatic compression on rat supraspinatus and Achilles tendons. Br. J. Sports Med. 2010, 44:698-703.
160. Torrente Y., et al. Tumor necrosis factor-alpha (TNF-alpha) stimulates chemotactic response in mouse myogenic cells. Cell Transplant. 2003, 12:91-100.
161. Urso M.L., et al. Matrix metalloprotease-3 and tissue inhibitor of metalloprotease-1 mRNA and protein levels are altered in response to traumatic skeletal muscle injury. Eur. J. Appl. Physiol. 2010, 109:963-972.
162. Van Saun M.N., Matrisian L.M. Matrix metalloproteinases and cellular motility in development and disease. Birth Defects Res. C Embryo Today 2006, 78:69-79.
163. Vanhoutte D., Heymans S. TIMPs and cardiac remodeling: embracing the MMP-independent-side of the family. J. Mol. Cell. Cardiol. 2010, 48:445-453.
164. Viappiani S., et al. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem. Pharmacol. 2009, 77:826-834.
165. Vincenti M.P., Brinckerhoff C.E. Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you?. J. Cell. Physiol. 2007, 213:355-364.
166. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003, 92:827-839.
167. Von Moers A., et al. Increased mRNA expression of tissue inhibitors of metalloproteinase-1 and -2 in Duchenne muscular dystrophy. Acta Neuropathol. 2005, 109:285-293.
168. Wang W., et al. Matrix metalloproteinase-1 promotes muscle cell migration and differentiation. Am. J. Pathol. 2009, 174:541-549.
169. Warren G.L., et al. Mechanisms of skeletal muscle injury and repair revealed by gene expression studies in mouse models. J. Physiol. 2007, 582:825-841.
170. Weaver A., et al. An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. FASEB J. 2005, 19:1668-1670.
171. Wittwer M., et al. Prolonged unloading of rat soleus muscle causes distinct adaptations of the gene profile. FASEB J. 2002, 16:884-886.
172. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991, 5:2145-2154.
173. Wu N., et al. Comparison of mouse matrix metalloproteinase 13 expression in free-electron laser and scalpel incisions during wound healing. J. Invest. Dermatol. 2003, 121:926-932.
174. Yagami-Hiromasa T., et al. A metalloprotease-disintegrin participating in myoblast fusion. Nature 1995, 377:652-656.
175. Yamada H., et al. Processing of beta-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum. Mol. Genet. 2001, 10:1563-1569.
176. Yan C., Boyd D.D. Regulation of matrix metalloproteinase gene expression. J. Cell. Physiol. 2007, 211:19-26.
177. Yan C., et al. Repression of 92-kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation. J. Biol. Chem. 2003, 278:2309-2316.
178. Yang Y., et al. Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J. Neurochem. 2010, 112:134-149.
179. Zanoteli E., et al. Muscle degeneration in neuraminidase 1-deficient mice results from infiltration of the muscle fibers by expanded connective tissue. Biochim. Biophys. Acta 2010, 1802:659-672.
180. Zanotti S., et al. Altered extracellular matrix transcript expression and protein modulation in primary Duchenne muscular dystrophy myotubes. Matrix Biol. 2007, 26:615-624.
181. Zanotti S., et al. Altered production of extra-cellular matrix components by muscle-derived Duchenne muscular dystrophy fibroblasts before and after TGF-β1 treatment. Cell Tissue Res. 2010, 339:397-410.
182. Zimowska M., et al. Distinct patterns of MMP-9 and MMP-2 activity in slow and fast twitch skeletal muscle regeneration in vivo. Int. J. Dev. Biol. 2008, 52:307-314.